Inhibrx Biosciences, Inc. 8-K

What Happened

• On April 21, 2026, Inhibrx Biosciences, Inc. announced clinical updates for ozekibart (INBRX-109) in late‑line colorectal cancer via a press release (Regulation FD disclosure). The press release is furnished as Exhibit 99.1 to the Form 8‑K.
• The company also posted an updated corporate presentation to the Investors section of its website and furnished that presentation as Exhibit 99.2 to the Form 8‑K. The report was signed by CFO Kelly Deck.

Key Details

• Date of filing/announcement: April 21, 2026.
• Product: ozekibart (INBRX-109), clinical updates in late‑line colorectal cancer.
• Materials furnished: Press release (Exhibit 99.1) and corporate presentation (Exhibit 99.2); presentation posted on www.inhibrx.com.
• Form 8‑K items reported: 7.01 (Regulation FD disclosure), 8.01 (Other events), and exhibits under 9.01.

Why It Matters

• Clinical updates for INBRX-109 are material to investors because they relate to Inhibrx’s drug pipeline and potential future value drivers; such news can affect investor interest and the company’s development outlook.
• The updated corporate presentation provides the investment community with the company’s latest program summaries and corporate messaging, facilitating investor review and analyst coverage.